Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer
Targeted Oncology · 20.10.2026
DOI: 10.1007/s11523-026-01237-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 20.10.2026. Verfasst von Jacob Sands und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215-5450, USA. jacob_sands@…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA..
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Vibostolimab, an anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) antibody, showed antitumor activity with pembrolizumab in non-small-cell lung cancer. OBJECTIVE: The KEYVIBE-008 study evaluated vibostolimab coformulated with pembrolizumab (vibostolimab/pembrolizumab) plus etoposide and platinum-based chemotherapy (EP) versus atezolizumab plus EP as first-line therapy for extensive-stage small-cell lung cancer. METHODS: Participants aged ≥18 years with untreated extensive-stage small-cell lung cancer were randomized 1:1 to vibostolimab/pembrolizumab (200 mg each) or atezolizumab (1200 mg) every 3 weeks, with EP and cisplatin/carboplatin for the first four cycles. The primary endpoint was overall survival. The prespecified interim analysis included a non-binding futility analysis of overall survival (futility threshold for actual number of events, P = 0.4816). RESULTS: Four hundred and sixty participants were randomized (both arms, n = 230). Median time from randomization to data cutoff (4 June, 2024) was 16.6 (range 11.3‒26.1) months. The prespecified futility criterion for overall survival was met (hazard ratio 1.26; 95% confidence interval 1.00‒1.59; P = 0.9762). There was no difference in progression-free survival (hazard ratio 1.01; 95% confidence interval 0.82‒1.23) or objective response rates (71.7% with vibostolimab/pembrolizumab vs 74.8% with atezolizumab). Grade ≥3 treatment-related adverse events occurred in 66.8% of participants treated with vibostolimab/pembrolizumab and 57.2% treated with atezolizumab. Immune-mediated adverse events and infusion reactions occurred in 39.3% and 29.7% of participants, respectively. CONCLUSIONS: In this interim analysis of vibostolimab/pembrolizumab plus EP versus atezolizumab plus EP as first-line therapy for extensive-stage small-cell lung cancer, the prespecified futility criterion for overall survival was met. Grade ≥3 treatment-related adverse events and immune-mediated adverse events were more frequent with vibostolimab/pembrolizumab versus atezolizumab. Given the overall benefit/risk profile, treatment with vibostolimab/pembrolizumab was discontinued. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT05224141.
Autor:innen und Institutionen
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215-5450, USA. jacob_sands@dfci.harvard.edu.
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Pulmonary Medicine, Erasmus MC University Hospital, Rotterdam, Netherlands.
- Department of Thoracic Oncology, Lungenclinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
- Vall d'Hebron Institut d'Oncology and Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
- Institute of Oncology, Rambam Medical Center, Haifa, Israel.
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Zitieren
APA
Sands, J., Lu, S., Aerts, J. G., Reck, M., Navarro, A., Shentzer Kutiel, T., Peled, N., Casarini, I., Kerr, S. J., Takahashi, T., Bilici, A., Cheng, Y., Wang, M., Lee, S. Y., Łowczak, A., Mazieres, J., Hu, H., Wu, J., Aggarwal, H., …, & Paz-Ares, L. (2026). Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. Targeted Oncology. https://doi.org/10.1007/s11523-026-01237-w
Vancouver
Sands J, Lu S, Aerts JG, Reck M, Navarro A, Shentzer Kutiel T, et al. Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. Targeted Oncology. 2026. doi:10.1007/s11523-026-01237-w
BibTeX
@article{Sands2026,
author = {Sands, Jacob and Lu, Shun and Aerts, Joachim G and Reck, Martin and Navarro, Alejandro and Shentzer Kutiel, Talia and Peled, Nir and Casarini, Ignacio and Kerr, Samuel J and Takahashi, Toshiaki and Bilici, Ahmet and Cheng, Ying and Wang, Mengzhao and Lee, Shin Yup and Łowczak, Anna and Mazieres, Julien and Hu, Haixia and Wu, Jianyu and Aggarwal, Himani and El-Osta, Hazem and Paz-Ares, Luis},
title = {Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer},
journal = {Targeted Oncology},
year = {2026},
doi = {10.1007/s11523-026-01237-w}
}
EUVIMED